A new analysis of an abandoned trial has resurrected Protagonist's lead asset, but the company has a long way to go and faces some stiff competition.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.